1. Introduction {#sec1}
===============

*TP53* tumor suppressor is the most commonly altered gene in human breast cancer where it is mutated in about 30--40% \[[@B1]\]. *TP53* gene mutations result in altered and stable p53 proteins that function as dominant negative with gain-of-function properties, including drug resistance, and contribute to malignant progression with detrimental effects on patient\'s outcome \[[@B2]\]. In particular, clinical evidence indicated that altered p53 proteins are prevalently associated with the pathologic class of triple-negative breast cancers, that is, tumors characterized by the immunohistochemical expression of basal cytokeratins and epidermal growth factor receptor (EGFR), but negative for estrogen (ER), progesterone receptor (PR), and HER2 expression \[[@B3]--[@B5]\]. Recently, triple-negative tumors have been also associated with a new less common subtype, known as claudin-low \[[@B6]\].

Wild-type p53 functions as a sequence-specific DNA binding transcription factor that regulates a plethora of target genes involved in DNA repair, cell cycle control, apoptosis, senescence, angiogenesis, and other fundamental biological process \[[@B7]\]. Therefore, it is not surprising that mutations of *TP53* gene or inactivations of its signaling pathway are prerequisite for the development of tumors. Most mutations occur within the central DNA binding domain (exons 5--8) and, in particular, at several specific amino acids required for DNA binding. According to the type of mutation (point mutation, deletion, insertion, or stop codon), p53 protein synthesis may be totally inhibited or may generate functionally altered molecules that affect cell homeostasis in a different manner \[[@B8]\]. In fact, it is well known that not all p53 mutations have equal effects: some of them confer loss of function, others have a dominant negative effect and still others are classified as wild-type-like protein and represent mutant forms with a limited biological effect \[[@B9], [@B10]\].

Recently, some excellent papers have provided experimental evidence linking loss of p53 function to the induction of epithelial-mesenchymal transition (EMT) and acquisition of stemness properties in different tumor cell lines \[[@B11]--[@B13]\]. EMT is a key program in embryonic development, the aberrant reactivation of which may induce progression, invasion, dissemination, and finally metastasis in cancer cells. The most evident peculiarities of a cell undergoing EMT process are loss of the epithelial phenotype and acquisition of mesenchymal features and abnormal motility capabilities \[[@B14], [@B15]\]. The most potent inducer of EMT is transforming growth factor-*β* (TGF-*β*) that triggers the activity of several transcription factors (ZEB1/TCF8, ZEB2/SIP1, Snail, Slug, Twist, and Ids), which in turn repress the expression of genes coding for epithelial markers and activate the expression of mesenchymal genes \[[@B16]\]. According to recent acquisition, p53 should prevent EMT by repressing ZEB1 and ZEB2 expressions via miRNAs activity. Consequently, p53 loss-of-function should downregulate miRNAs expression, the transactivation of transcription factors promoting EMT, and the emergence of tumor cells with stemlike properties \[[@B17]--[@B19]\].

So far, despite the availability of a huge amount of information on the transcript profile from microarray analysis, the interrelations among p53 mutations and genes involved in EMT have not been specifically assessed. Therefore, to investigate the association between *TP53* mutational status and EMT process, we interrogated a publicly accessible microarray dataset consisting of 251 p53 sequenced primary breast cancers \[[@B20]\]. Adopting an unconventional approach, we did not use the whole transcript profile but we selected *a priori* panel of genes experimentally recognized as involved in the canonical TGF-*β* signaling pathway and in two early events associated with EMT: loss of epithelial cell polarity and acquisition of stemness-associated features. To delineate a more comprehensive picture of the relationship among p53 mutation, EMT, and tumor aggressiveness, we also considered some genes involved in cell proliferation, apoptosis, and metastatic spread.

2. Materials and Methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

As reported in the original paper \[[@B20]\], gene expression profile was determined by using the Affymetrix Human Genome HG-U133A and -B GeneChip, and microarray dataset while was available at the ArrayExpress website (<http://www.ebi.ac.uk/arrayexpress/>), with the accession number E-GEOD-3494. Patients and tumors characteristics were provided as supporting information in the original paper \[[@B20]\].

2.2. Gene Selection {#sec2.2}
-------------------

According to the aim of the study, we selected 147 genes ([Table 1](#tab1){ref-type="table"}). Specifically, the panel was composed of 27 genes recognized as involved in TGF-*β*-induced EMT, 57 involved in epithelial cell plasticity, 13 coding for stemlike properties and 31 involved in cell proliferation, apoptosis, and metastatic spread. In addition, to describe breast cancer subtypes, 19 genes coding for luminal and basal markers were also considered. The 147 genes corresponded to 352 Affymetrix probe sets, as verified by GeneAnnot system v2.0 (<http://bioinfo2.weizmann.ac.il/geneannot/>), that additionally provided information about the quality of each probe set in terms of sensitivity and specificity score \[[@B21]\] (Supplementary Table 1 available at doi: 10.1155/2012/254085).

2.3. Statistical Analysis {#sec2.3}
-------------------------

As some genes are recognized by more than a single probe set, each of which characterized by an individual specificity and sensitivity that differently contribute to gene expression value, a gene expression mean value was calculated after weighting each probe set for its own sensitivity and specificity score. Specifically, each expression value (already log2 transformed in the original dataset) was multiplied for the semisum of sensitivity and specificity scores of the corresponding probe set.

Prediction Analysis for Microarray (PAM) analysis was used to identify genes associated with the *TP53* mutation status. PAM methodology minimizes the classification error using cross validation. For the selected genes, shrunken centroids across the different mutation groups were plotted. The FDR level was estimated through a permutation method.

To identify the tumors characterized by a similar intrinsic phenotype (tumor subtypes), unsupervised hierarchical cluster analysis was performed using the subset of genes coding for luminal and basal markers, HER-2, and claudins. The choice of the number of clusters to be used was supported by mean silhouette values \[[@B22]\]. PAM methodology was used to detail differential gene expression among clusters \[[@B23]\].

Principal Components Analysis (PCA) and PCA-based biplots were used to assess gene expression among clusters \[[@B24]\]. Moreover, for evaluating the associations among genes, specific subsets, not used to build PCA, were passively projected over the PCA-based biplots of intrinsic phenotypes.

All analyses were performed using open source software R 2.14.1 packages *stats, cluster*, and HDMD (<http://www.R-project.org/>).

3. Results and Discussion {#sec3}
=========================

As described in the original paper \[[@B20]\], the cases series was composed of 251 tumors, 58 of which characterized by a *TP53* mutation. Of the 58 mutant tumors, 37 had point mutations and 21 had "severe" mutations, that is, insertions (*n* = 3), deletions (*n* = 11), and stop codons (*n* = 7), that result in frame shift and truncations with deleterious functional consequences.

To identify genes differentially expressed between mutant and wild-type p53 tumors, we first applied a PAM analysis on the overall cases series ([Figure 1](#fig1){ref-type="fig"}). According to the expected loss-of-function, mutant p53 tumors were characterized by the underexpression of genes under p53 control (i.e., *CDKN1A,*coding for p21, and*TP53INP,*coding for the p53-inducible nuclear protein 1). In addition, they were showed as underxpressed several genes coding for epithelial cell polarity complex (*DLG4*, *DLG5, INADL, PARD3B, PARD6B*) and apical junctional components (*CLDN11*, *JAM2, JAM3, MAGI1, OCLN, PVRL2, TJP1, TJP3*). Conversely, mutant p53 tumors overexpressed *CDH2,*the gene coding for N-cadherin, and some genes involved in cell proliferation (*CCNE2*, *CDK4*, *CDK6, CDKN2A, CDKN2D, MKI67*) and metastatic spread (*CXCR4*, *MMP1*). An overall similar pattern of expression was found when we interrogated another publicly available microarray dataset where p53 mutational status was known \[[@B3]\] using the same panel of 147 genes. Despite the different microarray platform used (42K cDNA microarrays instead of Affymetrix GeneChip), mutant p53 tumors were associated with a dramatic underexpression of genes coding for apical junctional components (*INADL, JAM2, JAM3, MAGI1, PARD6B, PVRL2*) coupled with the overexpression of genes coding for N-cadherin (*CDH2*) or involved in cell proliferation and metastatic spread (*CCNE2, CDK4, CDK6, MKI67, MTA1*) (Supplementary Figure 1). Notably, in both datasets, p53 mutant tumors were associated with the overexpression of *PROM1*, supporting the experimental evidence indicating the relation among p53 mutation and the reacquisition of some stemlike properties according to an EMT-like process \[[@B12], [@B13]\].

As regards the genes related to the canonical TGF-*β* signaling pathway, mutant p53 tumors showed the downregulation of many genes coding for pivotal elements of this pathway (*ID1, ID4*, *SMAD3, SMAD4, SMAD5, TGFBR2*, *TGFBR3, ZEB1*) coupled with the overexpression of *SMURF2,*coding for a SMAD-specific E3 ubiquitin protein ligase, and*TGIF2,*coding for a transcriptional repressor interacting with TGF-*β* activated SMAD proteins ([Figure 2](#fig2){ref-type="fig"}). A similar pattern of expression (i.e., downregulation of *SMAD2, SMAD3, SMAD5, SMAD7, TGFBR2, ZEB1*, and overexpression of *SMURF2* and *TGIF2*) was found in Langerod dataset \[[@B3]\] (Supplementary Figure 2). This unexpected finding could be explained taking into account that TGF-*β* is a multifunctional cytokine and a powerful tumor suppressor that governs many aspects of mammary epithelial cells physiology and homeostasis \[[@B25]\]. Consistent with the notion that estrogen receptor and TGF-*β* signaling pathways are major regulators during mammary gland development \[[@B26]\], it is not surprising that p53 mutant tumors concomitantly underexpressed *ESR1*(coding for ER*α*),*TGFBR2, TGFBR3*(coding for TGF-*β* receptors) and *ID1, ID4, SMAD3, SMAD4, SMAD5, ZEB1*(coding for key elements of the pathway).

When severe and missense mutations were considered separately, PAM analysis provided evidence that severe *TP53* mutations were responsible for the differential gene expression observed in mutant with respect to wild-type p53 tumors, even though some important alterations were already present in missense *TP53* mutations, as, for example, the downregulation of some apical junctional components or the overexpression of genes related to cell proliferation and invasion. As shown in [Figure 3](#fig3){ref-type="fig"}, in addition to the expected decrease in the expression of *TP53, CDKN1A*, and *TP53INP1*, tumors harboring severe mutations were characterized by a dramatic overexpression of genes associated with proliferation (*CDK4, CDK6, MKI67*) and metastatic spread (*CXCR4, MMP1*), and by underexpression of several genes involved in epithelial cell identity (*DLG5, INADL, JAM2, JAM3, MAGI1, OCLN, PARD3B, PARD6B, PVRL2, SCRIB, TJP1* and *TJP3*).

As regards the association between missense or severe *TP53* mutation and EMT-related genes, [Figure 4](#fig4){ref-type="fig"} indicates that, with respect to tumors harboring a missense mutation, those with severe mutations were characterized by the overexpression of *SMURF2*, *SNAI1*, and *TGIF2*genes. Of particular interest is the overexpression of *SNAI1* gene because of the concomitant overexpression of *NOTCH1* pointed out by PAM analysis in tumors with severe *TP53* mutation ([Figure 3](#fig3){ref-type="fig"}). Indeed, Notch signalling pathway, which is implicated as an important contributor to EMT in tumorigenesis, has been recently suggested to play a direct role on the expression of the Snail transcription factor \[[@B27]\].

With respect to missense *TP53* mutations, severe ones were also characterized by an increased expression of *PROM1,* the gene encoding for prominin, a pentaspan transmembrane glycoprotein (CD133) often overexpressed on cancer cells, where it is thought to function in maintaining stem cell properties by suppressing differentiation. This finding is in agreement with the hypothesis that basal cancers, which have been proposed to have a stem cell origin, are virtually all *TP53* mutants and express high levels of *PROM1* transcript and protein \[[@B28]\]. Unfortunately, since in Langerod dataset \[[@B3]\] severe mutations accounted for only three cases, we were unable to verify all these observations in an independent dataset.

One of the aims of the study was to explore the relationship among p53 mutation, EMT, and tumor aggressiveness, a peculiar characteristic of certain breast cancer subtypes (especially basal-like phenotype). To this specific aim, we performed an unsupervised hierarchical cluster analysis, using the subset of genes coding for luminal and basal markers, HER-2, and claudins, and we looked at the distribution of p53 mutations according to tumor subtype. The analysis indicated that mutant p53 tumors distributed into three main clusters ([Figure 5](#fig5){ref-type="fig"}). Of the 58 mutant p53 tumors, 23 were included in Cluster 1, 17 in Cluster 2, and 18 in Cluster3. However, looking at the relative percentage, we found that, on the total number of tumors in each cluster, only 17% (23/133) of Cluster 1 and 19% (18/95) of Cluster 3 tumors had p53 mutations, whereas 74% (17/23) of Cluster 2 tumors did have. Notably, 10 of these 17 mutations were severe mutations.

PCA-based biplots, drawn using the same subset of genes of hierarchical cluster analysis ([Figure 6](#fig6){ref-type="fig"}), showed that Cluster 2 tumors were positively associated with genes related to basal phenotype (*KRT5, KRT6A, KRT6B, KRT14, KRT17, EGFR*) and with a panel of claudin-coding genes (*CLDN1, CLDN6, CLDN10*), whereas they were negatively associated with the majority of genes related to luminal phenotype. Conversely, Cluster 3 tumors were positively associated with genes related to luminal phenotype (*ESR1, GATA3, MUC1, PGR, KRT18*) and with a different panel of claudin-coding genes (*CLDN3, CLDN4, CLDN7*) and negatively associated with genes related to basal phenotype. Cluster 1 tumors showed a less clear-cut phenotype according to the more heterogeneous nature of this cluster, even though they appeared prevalently, associated with genes related to basal phenotype (*KRT5, KRT6B, KRT14, KRT17, TP63*). Remarkably, Cluster 2 tumors also showed the concomitant underexpression of *ERBB2* gene providing evidence that these tumors had a gene expression profile consistent with the pathologic class of triple-negative tumors (Supplementary Figure 3), which are characterized by the expression of basal cytokeratins (mainly Krt5) and EGFR, but do not express estrogen and progesterone receptors, and HER2.

When we looked at the expression of EMT-associated genes according to clusters ([Figure 7](#fig7){ref-type="fig"}), we found that Cluster 2, consistent with the pathologic class of triple-negative cancers, showed a gene expression profile similar to that of tumors harboring a severe p53 mutation. Conversely, Cluster 3, consistent with the luminal-like phenotype, had a pattern of expression similar to that of wild-type p53 tumors whereas the phenotypically heterogenous Cluster 1 looks like the group of tumors with a missense p53 mutation. In particular, Cluster 2 (consistent with the pathologic class of triple-negative cancers and akin to severe p53 mutated tumors) was characterized by the underexpression of *SMAD2, SMAD5, ZEB1*, and *TGFBR3* and the overexpression of *SMURF2, TGIF2*, and *SNAI1,* in agreement with the gene profile observed in tumors harboring a severe *TP53* mutation ([Figure 4](#fig4){ref-type="fig"}).

Notably, when the subset of genes related to stemness properties was passively projected over the PCA-based biplots provided in [Figure 6](#fig6){ref-type="fig"}, Cluster 2 tumors were positively associated with *PROM1* and *NOTCH1,* and negatively associated with *ALDH1A1, BMI1, NUMB*([Figure 8](#fig8){ref-type="fig"}). Similar to the latter but opposite in the sign, was the pattern of association shown by Cluster 3 tumors.

The imbalance in Numb/Notch pathway observed in Cluster 2 tumors, associated with the overexpression of *SNAI1,* is of particular interest because the involvement of this pathway in differentiation program and epithelial cancer progression and metastasis. Numb is an evolutionary conserved protein that plays a critical role in cell-fate determination, including control of asymmetric cell division, endocytosis, cell adhesion, cell migration, and ubiquitination of specific substrates as p53. Loss of Numb causes increased activity of the oncogene Notch1 and for this reason, low expression of Numb and high levels of Notch1 have been associated with tumor progression and used as markers of tumor aggressiveness, especially in basal-like breast cancer \[[@B29]\]. The aggressiveness of this group of tumors was corroborated by the observation that Cluster 2 tumors were prevalently poorly differentiated (17/23 tumors were Grade III) with respect to Cluster 1 and Cluster 3 tumors, and by the positive association with genes promoting cell proliferation and metastatic spread. In this context, it can be viewed the overexpression of *MMP1* and *CXCR4*, and the downregulation of*TIMP1.*Indeed*, MMP1* encodes for a matrix metalloproteinase family member (specifically, a collagenase) involved in the breakdown of extracellular matrix whereas *TIMP1* encodes for a specific tissue inhibitor of metalloproteases, including MMP-1. Because *MMP1* is a target gene for wild-type p53 activity, the functional inactivation of the protein results in a gene overexpression that allows tumor cell migration after degradation of basement membrane and cell detachment \[[@B30], [@B31]\]. The concomitant overexpression of *CXCR4* due to a gain-of-function mutant p53 \[[@B32], [@B33]\], further contributes to enhance tumor cell migration and metastatic spread \[[@B34]\]. In fact, *CXCR4* encodes a C-X-C motif chemokine receptor specific for stromal cell-derived factor-1 (SDF-1/CXCL12), a member of the family of chemoattractant molecules, physiologically involved in the migration of immune cells. The CXCL12/CXCR4 signaling axis is also known to be important for tumor cell migration: CXCR4 expressed on tumor cells, provides a means of homing for metastatic cells to target organs \[[@B35]\]. Due to its implication with tumor dissemination, *CXCR4* overexpression has been linked to a poor prognosis in breast cancer patients \[[@B35]\].

Surprisingly, on the contrary, it should be the negative association, pointed out by PCA-based biplots, between Cluster 2 tumors and *BMI1* expression. That, because the role of *BMI1* gene in self-renewal of stem cells and as an oncogene in many human cancers where it induces EMT. Although Bmi1 overexpression has been correlated with poor prognosis in several tumor types, a recent study has indicated that, in breast cancer, high Bmi1 expression is limited to the luminal subtype and that it is associated with a good outcome \[[@B36]\]. Under this light, the positive association that we observed between *BMI1* expression and Cluster 3 tumors, consistent with the luminal-like phenotype, seems to provide a transcriptomic support to this clinical evidence.

Cluster 1 tumors, which are prevalently p53 wild-type, are more difficult to categorize. Dissimilarly from basal-like and luminal-like, these tumors had an indefinite phenotype characterized by the coexpression of luminal and basal cytokeratins. In addition, the overexpression of several transcription factors (*ID2, ID4, SNAI2, TWIST1, ZEB2*), known to be under TGF-*β* control, and the concomitant overexpression of some genes coding for stemlike properties (*ABCG2, JAG1, JAG2, NANOG, NOTCH4*) makes it difficult to have a correct interpretation of the results. Indeed, it is not easy to establish whether such a phenotypical heterogeneity represents an intermediate step of an EMT-like process, in which tumor cells gain characteristics of mesenchymal cells but have not completely lost epithelial characteristics, or it is simply due to the individual heterogeneity of the tumors forming the cluster.

4. Conclusions {#sec4}
==============

Aim of this *in silico* study was to investigate the association between *TP53* mutational status and expression of a panel of genes related to TGF-*β* induced EMT and stemlike features, using a publicly accessible microarray dataset consisting of 251 p53-sequenced primary breast cancers. According to recent experimental evidence linking loss of p53 function, induction of EMT and acquisition of stemness properties in different tumor cell lines \[[@B11]--[@B13]\], we expected an evident positive association between EMT-related genes and p53 mutations, in particular with severe p53 mutations. In addition, since clinical evidence indicates that p53 mutations are prevalently associated with the pathologic class of triple-negative breast cancers, we expected an overexpression of EMT-related genes in this specific subset of tumors. Our analysis supports the notion that mutant p53 tumors (especially those harboring a severe p53 mutation) were consistent with the aggressive clinic class of triple-negative cancers, but it clearly indicates that, differently from cell cultures \[[@B11]--[@B13]\], surgical tumors did not overexpress TGF-*β*-related transcription factors. Taking into account the physiological role of TGF-*β* in mammary gland differentiation \[[@B25], [@B26]\], these unexpected findings seem to suggest an interesting relationship between p53 mutation, mammary cell dedifferentiation, and the concomitant acquisition of stemlike properties which improve tumor cells aggressiveness.

Supplementary Material {#supplementary-material-sec}
======================

###### 

Supplementary Table: lists the 352 Affymetrix probe sets corresponding to the 147 genes entered in the study. For each probe set sensitivity and specificity score are also provided.

Supplementary Figure 1: shows shrunken centroids for wild-type TP53 and mutant TP53 tumors in Langerod dataset (for details see Statistical Analysis description).

Supplementary Figure 2: shows the boxplots of the genes associated with EMT in wild-type (WT) or mutant (mut) TP53 tumors with respect to overall case series (all), in Langerod dataset (for details see Statistical Analysis description).

Supplementary Figure 3: shows the boxplots of the ESR1, PGR, ERBB2, TP53 and TP53INP genes in the three main clusters identified by unsupervised hierarchical cluster analysis using the subset of genes coding for luminal and basal markers, ERBB2 and claudins (for details see Statistical Analysis description).

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

###### 

Click here for additional data file.

![Shrunken centroids for wild-type *TP53* and mutant *TP53* tumors. Left-sided bars indicate lower expression in the subgroups relative to overall centroid; right-sided bars indicate higher expression in subgroups relative to overall centroid.](JBB2012-254085.001){#fig1}

![Boxplots of the genes associated with EMT in wild-type (WT) or mutant (mut) *TP53* tumors with respect to overall case series (all).](JBB2012-254085.002){#fig2}

![Shrunken centroids for wild-type *TP53* an mutant (missense or severe mutation) *TP53* tumors. Left-sided bars indicate lower expression in the subgroups relative to overall centroid; right-sided bars indicate higher expression in subgroups relative to overall centroid.](JBB2012-254085.003){#fig3}

![Boxplots of the genes associated with EMT in wild-type (WT), missense (MS), or severe (SV) *TP53* mutation with respect to overall case series (all).](JBB2012-254085.004){#fig4}

![Tumor dendrogram from clustering 251 tumors and 30 genes associated with intrinsic breast cancer phenotypes (luminal, basal, *ERBB2*, and claudins). Black bars denote tumors with a wild-type p53; orange bars, tumors with a mutant p53 (missense mutation); red bars, tumors with a mutant p53 (severe mutation).](JBB2012-254085.005){#fig5}

![Active PCA-based biplots of intrinsic breast cancer phenotype-related genes. Samples are colored according to the mutational p53 status (wild-type in green and mutant in blue) and are labeled according to the corresponding cluster (1, 2, or 3). Loading for basal genes are represented by red arrows, luminal genes by pink arrows, claudin genes by orange arrows, and *ERBB2* gene by yellow arrow.](JBB2012-254085.006){#fig6}

![Boxplots of the genes associated with EMT in the three main clusters identified by unsupervised hierarchical cluster analysis using the subset of genes coding for luminal and basal markers, HER-2 and claudins.](JBB2012-254085.007){#fig7}

![Passive projectionof stemlike-related genes in the space of the first two principal components (PC), (a), and in the space of first and third PCs, (b), of intrinsic phenotype gene set. Loading for EMT or stemlike genes are represented in black.](JBB2012-254085.008){#fig8}

###### 

Genes entered in the study.

                                      Official gene symbol                                                                      Gene name                                             Entrez gene ID   Ensembl genomic location
  ----------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------- ---------------- --------------------------
  Apical junctional complex           *CDH1*                                                                                    Cadherin 1, type 1, E-cadherin (epithelial)           999              16q22.1
  *CDH2*                              Cadherin 2, type 1, N-cadherin (neuronal)                                                 1000                                                  18q12.1          
  *CLDN1*                             Claudin 1                                                                                 9076                                                  3q28             
  *CLDN2*                             Claudin 2                                                                                 9075                                                  Xq22.3           
  *CLDN3*                             Claudin 3                                                                                 1365                                                  7q11.23          
  *CLDN4*                             Claudin 4                                                                                 1364                                                  7q11.23          
  *CLDN5*                             Claudin 5                                                                                 7122                                                  22q11.21         
  *CLDN6*                             Claudin 6                                                                                 9074                                                  16p13.3          
  *CLDN7*                             Claudin 7                                                                                 1366                                                  17p13.1          
  *CLDN8*                             Claudin 8                                                                                 9073                                                  21q22.11         
  *CLDN9*                             Claudin 9                                                                                 9080                                                  16p13.3          
  *CLDN10*                            Claudin 10                                                                                9071                                                  13q32.1          
  *CLDN11*                            Claudin 11                                                                                5010                                                  3q26.2           
  *CLDN12*                            Claudin 12                                                                                9069                                                  7q21.13          
  *CLDN14*                            Claudin 14                                                                                23562                                                 21q22.3          
  *CLDN15*                            Claudin 15                                                                                24146                                                 7q22.1           
  *CLDN16*                            Claudin 16                                                                                10686                                                 3q28             
  *CLDN17*                            Claudin 17                                                                                26285                                                 21q22.11         
  *CLDN18*                            Claudin 18                                                                                51208                                                 3q22.3           
  *CLDN23*                            Claudin 23                                                                                137075                                                8p23.1           
  *CTNNA1*                            Catenin (cadherin-associated protein), alpha 1                                            1495                                                  5q31.2           
  *CTNNB1*                            Catenin (cadherin-associated protein), beta 1                                             1499                                                  3p22.1           
  *CTNND1*                            Catenin (cadherin-associated protein), delta 1                                            1500                                                  11q12.1          
  *JAM2*                              Junctional adhesion molecule 2                                                            58494                                                 21q21.3          
  *JAM3*                              Junctional adhesion molecule 3                                                            83700                                                 11q25            
  *JUP*                               Junction plakoglobin                                                                      3728                                                  17q21.2          
  *MAGI1*                             Membrane associated guanylate kinase, WW and PDZ domain containing 1                      9223                                                  3p14.1           
  *MARVELD2*                          MARVEL domain containing 2                                                                153562                                                5q13.2           
  *OCLN*                              Occludin                                                                                  4950                                                  5q13.2           
  *PVRL1*                             Poliovirus receptor-related 1 (herpesvirus entry mediator C)                              5818                                                  11q23.3          
  *PVRL2*                             Poliovirus receptor-related 2 (herpesvirus entry mediator B)                              5819                                                  19q13.32         
  *PVRL3*                             Poliovirus receptor-related 3                                                             25945                                                 3q13.13          
  *PVRL4*                             Poliovirus receptor-related 4                                                             81607                                                 1q23.3           
  *SYMPK*                             Symplekin                                                                                 8189                                                  19q13.32         
  *TJP1*                              Tight junction protein 1 (zona occludens 1)                                               7082                                                  15q13.1          
  *TJP2*                              Tight junction protein 2 (zona occludens 2)                                               9414                                                  9q21.11          
  *TJP3*                              Tight junction protein 3 (zona occludens 3)                                               27134                                                 19p13.3          
  *VCL*                               Vinculin                                                                                  7414                                                  10q22.2          
                                                                                                                                                                                                       
  Apoptosis                           *BAX*                                                                                     BCL2-associated X protein                             581              19q13.33
  *BCL2*                              B-cell CLL/lymphoma 2                                                                     596                                                   18q21.33         
  *CASP2*                             Caspase 2, apoptosis-related cysteine peptidase                                           835                                                   7q34             
  *ERBB2*                             V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (avian)                         2064                                                  17q12            
  *MDM2*                              Mdm2 p53 binding protein homolog (mouse)                                                  4193                                                  12q15            
  *TP53*                              Tumor protein p53                                                                         7157                                                  17p13.1          
  *TP53INP1*                          Tumor protein p53 inducible nuclear protein 1                                             94241                                                 8q22.1           
  *XIAP*                              X-linked inhibitor of apoptosis                                                           331                                                   Xq25             
                                                                                                                                                                                                       
  Basal markers                       *ACTA1*                                                                                   Actin, alpha 1, skeletal muscle                       58               1q42.13
  *CD44*                              CD44 molecule (Indian blood group)                                                        960                                                   11p13            
  *EGFR*                              Epidermal growth factor receptor                                                          1956                                                  7p11.2           
  *KRT5*                              Keratin 5                                                                                 3852                                                  12q13.13         
  *KRT6A*                             Keratin 6A                                                                                3853                                                  12q13.13         
  *KRT6B*                             Keratin 6B                                                                                3854                                                  12q13.13         
  *KRT14*                             Keratin 14                                                                                3861                                                  17q21.2          
  *KRT17*                             Keratin 17                                                                                3872                                                  17q21.2          
  *TP63*                              Tumor protein p63                                                                         8626                                                  3q28             
  *VIM*                               Vimentin                                                                                  7431                                                  10p13            
                                                                                                                                                                                                       
  Cell cycle                          *CCNB3*                                                                                   Cyclin B3                                             85417            Xp11.22
  *CCND1*                             Cyclin D1                                                                                 595                                                   11q13.3          
  *CCNE2*                             Cyclin E2                                                                                 9134                                                  8q22.1           
  *CDK2*                              Cyclin-dependent kinase 2                                                                 1017                                                  12q13.2          
  *CDK4*                              Cyclin-dependent kinase 4                                                                 1019                                                  12q14.1          
  *CDK6*                              Cyclin-dependent kinase 6                                                                 1021                                                  7q21.2           
  *CDKN1A*                            Cyclin-dependent kinase inhibitor 1A (p21, Cip1)                                          1026                                                  6p21.2           
  *CDKN1B*                            Cyclin-dependent kinase inhibitor 1B (p27, Kip1)                                          1027                                                  12p13.1          
  *CDKN2A*                            Cyclin-dependent kinase inhibitor 2A (melanoma, p16, CDK4)                                1029                                                  9p21.3           
  *CDKN2B*                            Cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)                                 1030                                                  9p21.3           
  *CDKN2D*                            Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4)                                 1032                                                  19p13.2          
  *GAS1*                              Growth arrest-specific 1                                                                  2619                                                  9q21.33          
  *MKI67*                             Antigen identified by monoclonal antibody Ki-67                                           4288                                                  10q26.2          
                                                                                                                                                                                                       
  Cell polarity complexes             *CRB1*                                                                                    Crumbs homolog 1(*Drosophila*)                        23418            1q31.3
  *CRB3*                              Crumbs homolog 3 (*Drosophila*)                                                           92359                                                 19p13.3          
  *DLG1*                              Discs, large homolog 1 (*Drosophila*)                                                     1739                                                  3q29             
  *DLG2*                              Discs, large homolog 2 (*Drosophila*)                                                     1740                                                  11q14.1          
  *DLG3*                              Discs, large homolog 3 (*Drosophila*)                                                     1741                                                  Xq13.1           
  *DLG4*                              Discs, large homolog 4 (*Drosophila*)                                                     1742                                                  17p13.1          
  *DLG5*                              Discs, large homolog 5 (*Drosophila*)                                                     9231                                                  10q22.3          
  *INADL*                             InaD-like (*Drosophila*)                                                                  10207                                                 1p31.3           
  *MPP5*                              Membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5)                          64398                                                 14q23.3          
  *LLGL1*                             Lethal giant larvae homolog 1 (*Drosophila*)                                              3996                                                  17p11.2          
  *LLGL2*                             Lethal giant larvae homolog 2 (*Drosophila*)                                              3993                                                  17q25.1          
  *PARD3*                             Par-3 partitioning defective 3 homolog (*C. elegans*)                                     56288                                                 10p11.21         
  *PARD3B*                            Par-3 partitioning defective 3 homolog B (*C. elegans*)                                   117583                                                2q33.3           
  *PARD6A*                            Par-6 partitioning defective 6 homolog alpha (*C. elegans*)                               50855                                                 16q22.1          
  *PARD6B*                            Par-6 partitioning defective 6 homolog beta (*C. elegans*)                                84612                                                 20q13.13         
  *PARD6G*                            Par-6 partitioning defective 6 homolog gamma (*C. elegans*)                               84552                                                 18q23            
  *PRKCI*                             Protein kinase C, iota                                                                    5584                                                  3q26.2           
  *PRKCZ*                             Protein kinase C, zeta                                                                    5590                                                  1p36.33          
  *SCRIB*                             Scribbled homolog (*Drosophila*)                                                          23513                                                 8q24.3           
                                                                                                                                                                                                       
  Epithelial-mesenchymal transition   *AKT1*                                                                                    V-akt murine thymoma viral oncogene homolog 1         207              14q32.33
  *AKT2*                              V-akt murine thymoma viral oncogene homolog 2                                             208                                                   19q13.2          
  *BMP1*                              Bone morphogenetic protein 1                                                              649                                                   8p21.3           
  *ID1*                               Inhibitor of DNA binding 1, dominant negative helix-loop-helix protein                    3397                                                  20q11.21         
  *ID2*                               Inhibitor of DNA binding 2, dominant negative helix-loop-helix protein                    3398                                                  2p25.1           
  *ID3*                               Inhibitor of DNA binding 3, dominant negative helix-loop-helix protein                    3399                                                  1p36.12          
  *ID4*                               Inhibitor of DNA binding 4, dominant negative helix-loop-helix protein                    3400                                                  6p22.3           
  *SMAD2*                             SMAD family member 2                                                                      4087                                                  18q21.1          
  *SMAD3*                             SMAD family member 3                                                                      4088                                                  15q22.33         
  *SMAD4*                             SMAD family member 4                                                                      4089                                                  18q21.2          
  *SMAD5*                             SMAD family member 5                                                                      4090                                                  5q31.1           
  *SMAD6*                             SMAD family member 6                                                                      4091                                                  15q22.31         
  *SMAD7*                             SMAD family member 7                                                                      4092                                                  18q21.1          
  *SMURF1*                            SMAD specific E3 ubiquitin protein ligase 1                                               57154                                                 7q22.1           
  *SMURF2*                            SMAD specific E3 ubiquitin protein ligase 2                                               64750                                                 17q24.1          
  *SNAI1*                             Snail homolog 1 (*Drosophila*)                                                            6615                                                  20q13.13         
  *SNAI2*                             Snail homolog 2 (*Drosophila*)                                                            6591                                                  8q11.21          
  *TCF3*                              Transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)              6929                                                  19p13.3          
  *TGFBI*                             Transforming growth factor, beta-induced, 68 kDa                                          7045                                                  5q31.1           
  *TGFBR1*                            Transforming growth factor, beta receptor 1                                               7046                                                  9q22.33          
  *TGFBR2*                            Transforming growth factor, beta receptor II                                              7048                                                  3p24.1           
  *TGFBR3*                            Transforming growth factor, beta receptor III                                             7049                                                  1p22.1           
  *TGIF2*                             TGFB-induced factor homeobox 2                                                            60436                                                 20q11.23         
  *TWIST1*                            Twist homolog 1 (*Drosophila*)                                                            7291                                                  7p21.1           
  *TWIST2*                            Twist homolog 2 (*Drosophila*)                                                            117581                                                2q37.3           
  *ZEB1*                              Zinc finger E-box binding homeobox 1                                                      6935                                                  10p11.22         
  *ZEB2*                              Zinc finger E-box binding homeobox 2                                                      9839                                                  2q22.3           
                                                                                                                                                                                                       
  Luminal markers                     *CD24*                                                                                    CD24 molecule                                         100133941        6q21
  *ESR1*                              Estrogen receptor 1                                                                       2099                                                  6q25.1           
  *GATA3*                             GATA binding protein 3                                                                    2625                                                  10p14            
  *KRT7*                              Keratin 7                                                                                 3855                                                  12q13.13         
  *KRT8*                              Keratin 8                                                                                 3856                                                  12q13.13         
  *KRT18*                             Keratin 18                                                                                3875                                                  12q13.13         
  *KRT19*                             Keratin 19                                                                                3880                                                  17q21.2          
  *MUC1*                              Mucin 1, cell surface associated                                                          4582                                                  1q22             
  *PGR*                               Progesterone receptor                                                                     5241                                                  11q22.1          
                                                                                                                                                                                                       
  Metastasis-related genes            *CXCR4*                                                                                   Chemokine (C-X-C motif) receptor 4                    7852             2q22.1
  *CXCR5*                             Chemokine (C-X-C motif) receptor 5                                                        643                                                   11q23.3          
  *MMP1*                              Matrix metallopeptidase 1 (interstitial collagenase)                                      4312                                                  11q22.2          
  *MMP2*                              Matrix metallopeptidase 2 (gelatinase A, 72 kDa gelatinase, 72 kDa type IV collagenase)   4313                                                  16q12.2          
  *MMP3*                              Matrix metallopeptidase 3 (stromelysin 1, progelatinase)                                  4314                                                  11q22.2          
  *MTA1*                              Metastasis associated 1                                                                   9112                                                  14q32.33         
  *MTA2*                              Metastasis associated 1 family, member 2                                                  9219                                                  11q12.3          
  *MTA3*                              Metastasis associated 1 family, member 3                                                  57504                                                 2p21             
  *PAK6*                              P21 protein (Cdc42/Rac)-activated kinase 6                                                56924                                                 15q15.1          
  *TIMP1*                             TIMP metallopeptidase inhibitor 1                                                         7076                                                  Xp11.23          
                                                                                                                                                                                                       
  Stemlike features                   *ABCG2*                                                                                   ATP-binding cassette, sub-family G (WHITE),member 2   9429             4q22.1
  *ALDH1A1*                           Aldehyde dehydrogenase 1 family, member A1                                                216                                                   9q21.13          
  *ALDH1A3*                           Aldehyde dehydrogenase 1 family, member A3                                                220                                                   15q26.3          
  *BMI1*                              BMI1 polycomb ring finger oncogene                                                        648                                                   10p12.2          
  *JAG1*                              Jagged 1                                                                                  182                                                   20p12.2          
  *JAG2*                              Jagged 2                                                                                  3714                                                  14q32.33         
  *NANOG*                             Nanog homeobox                                                                            79923                                                 12p13.31         
  *NOTCH1*                            Notch 1                                                                                   4851                                                  9q34.3           
  *NOTCH2*                            Notch homolog 2 (*Drosophila*)                                                            4853                                                  1p12             
  *NOTCH3*                            Notch homolog 3 (*Drosophila*)                                                            4854                                                  19p13.12         
  *NOTCH4*                            Notch homolog 4 (*Drosophila*)                                                            4855                                                  6p21.32          
  *NUMB*                              Numb homolg (*Drosophila*)                                                                8650                                                  14q24.3          
  *PROM1*                             Prominin 1                                                                                8842                                                  4p15.32          

[^1]: Academic Editor: F. C. Schmitt
